Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Oct;22(4):479–482. doi: 10.1111/j.1365-2125.1986.tb02921.x

Different effects of metoclopramide and domperidone on arginine-vasopressin secretion in man.

P Chiodera, R Volpi, R Delsignore, C Marchesi, G Salati, L Camellini, G Rossi, V Coiro
PMCID: PMC1401167  PMID: 3768259

Abstract

This study was performed in order to investigate the dopaminergic mechanism involved in the control of arginine-vasopressin (AVP) secretion in normal men. Plasma AVP concentrations were measured before and after the administration of an i.v. bolus of 10 mg metoclopramide or domperidone to twelve healthy males. Metoclopramide, a cerebral and peripheral antagonist of dopaminergic receptors, significantly stimulated AVP secretion, whereas domperidone, a dopamine antagonist which does not cross the blood-brain barrier, was without effect. These data suggest that metoclopramide stimulates the release of AVP by blocking dopaminergic receptors in structures located inside the blood-brain barrier. Alternatively, it is possible that the stimulation of AVP release induced by metoclopramide does not occur through inhibition of dopamine receptors but rather through interaction with other neuroendocrine pathways.

Full text

PDF
479

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baudry M., Martres M. P., Schwartz J. C. 3H-Domperidone: a selective ligand for dopamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1979 Sep;308(3):231–237. doi: 10.1007/BF00501387. [DOI] [PubMed] [Google Scholar]
  2. Chiodera P., Coiro V., Volpi R., Roti E. Pizotifen, an antiserotonergic drug, induced inhibition of the GH-stimulating activity of metoclopramide in normal women. Horm Metab Res. 1984 Aug;16(8):450–451. doi: 10.1055/s-2007-1014814. [DOI] [PubMed] [Google Scholar]
  3. Chiodera P., Louis F., Legros J. J. Simultaneous radioimmunoassay for plasma arginine-vasopressin and oxytocin using DEAE Sephadex A 25 extraction. J Endocrinol Invest. 1984 Aug;7(4):287–293. doi: 10.1007/BF03351004. [DOI] [PubMed] [Google Scholar]
  4. Cuello A. C., Iversen L. L. Localization of tritiated dopamine in the median eminence of the rat hypothalamus by electron microscope autoradiography. Brain Res. 1973 Dec 7;63:474–478. doi: 10.1016/0006-8993(73)90127-3. [DOI] [PubMed] [Google Scholar]
  5. Fang V. S., Shian L. R. A serotonergic mechanism of the prolactin-stimulating action of metoclopramide. Endocrinology. 1981 May;108(5):1622–1627. doi: 10.1210/endo-108-5-1622. [DOI] [PubMed] [Google Scholar]
  6. Jungmann E., Althoff P. H., Hermann G. J., Schöffling K. The effect of pizotifen, a serotonin antagonist, and of pirenzepine, a muscarinic antagonist, on hormonal responses to metoclopramide in healthy subjects. Arzneimittelforschung. 1984;34(9):1022–1024. [PubMed] [Google Scholar]
  7. Laduron P. M., Leysen J. E. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol. 1979 Jul 15;28(14):2161–2165. doi: 10.1016/0006-2952(79)90198-9. [DOI] [PubMed] [Google Scholar]
  8. Loizou L. A. Uptake of monoamines into central neurones and the blood-brain barrier in the infant rat. Br J Pharmacol. 1970 Dec;40(4):800–813. doi: 10.1111/j.1476-5381.1970.tb10656.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Miller R. Metoclopramide and dopamine receptor blockade. Neuropharmacology. 1976 Aug;15(8):463–469. doi: 10.1016/0028-3908(76)90056-3. [DOI] [PubMed] [Google Scholar]
  10. Nomura K., Kurimoto F., Demura H., Sakurai H., Nomura T., Zibiki K., Naruse M., Kanai N., Shizume K. Effect of metoclopramide in plasma vasopressin in man. Clin Endocrinol (Oxf) 1984 Aug;21(2):117–121. doi: 10.1111/j.1365-2265.1984.tb03450.x. [DOI] [PubMed] [Google Scholar]
  11. Parry H. B., Livett B. G. A new hypothalamic pathway to the median eminence containing neurophysin and its hypertrophy in sheep with natural scrapie. Nature. 1973 Mar 2;242(5392):63–65. doi: 10.1038/242063a0. [DOI] [PubMed] [Google Scholar]
  12. Sklar A. H., Schrier R. W. Central nervous system mediators of vasopressin release. Physiol Rev. 1983 Oct;63(4):1243–1280. doi: 10.1152/physrev.1983.63.4.1243. [DOI] [PubMed] [Google Scholar]
  13. Zimmerman E. A., Carmel P. W., Husain M. K., Ferin M., Tannenbaum M., Frantz A. G., Robinson A. G. Vasopressin and neurophysin: high concentrations in monkey hypophyseal portal blood. Science. 1973 Nov 20;182(4115):925–927. doi: 10.1126/science.182.4115.925. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES